登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600587 证券简称：新华医疗 公告编号：临2025-041 山东新华医疗器械股份有限公司 关于控股股东增持计划进展暨权益变动触及1%刻度的提示性公告 控股股东山东颐养健康产业发展集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 1.身份类别 ■ 2.信息披露义务人信息 上述信息披露义务人无一致行动人。 二、权益变动触及1%刻度的基本情况 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 本次权益变动为山东新华医疗器械股份有限公司（以下简称"公司"）控股股东山东颐养健康产业发展 集团有限公司（以下简称"山东健康集团"）按照增持计划增持公司股份，不触及要约收购，不会导致公 司控股股东及实际控制人发生变化。 ● 本次权益变动后，山东健康集团合计持有公司股份175,936,527股，占公司总股本的29.00%。 ■ 一、信息披露义务人及其一致行动人的基本信息 ■ 三、其他说明 1.本次权益变动为山东健康集团履行此前披露的增持股份计划，不触及要约收购。 2.本次权益变动不会导致 ...

| 权益变动方向 | 比例增加☑ | | 比例减少□ | | --- | --- | --- | --- | | 权益变动前合计比例 | 28.91% | | | | 权益变动后合计比例 | 29.00% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否☑ | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 一、 信息披露义务人及其一致行动人的基本信息 证券代码：600587 证券简称：新华医疗 公告编号：临 2025-041 山东新华医疗器械股份有限公司 关于控股股东增持计划进展暨权益变动触及 1%刻度的提示性公告 控股股东山东颐养健康产业发展集团有限公司保证向本公司提供的信息真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次权益变动为山东新华医疗器械股份有限公司（以下简称"公司"） 控股股东山东颐养健康产业发展集团有限公司（以下简称"山东健康集团"）按 照增持计划增持公司股份，不触及要约收购，不会导致公司控股股东及实际控制 人发生变化。 本次权益变动后，山东健康集团合计 ...

Core Viewpoint - The company, Shandong Xinhua Medical Instrument Co., Ltd., is set to hold an investor briefing on October 16, 2025, to discuss its 2025 semi-annual performance and financial results, allowing for interactive communication with investors [2][3]. Group 1: Meeting Details - The investor briefing will take place on October 16, 2025, from 15:00 to 16:00 [2][8]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [2][8]. - The meeting will be conducted in an interactive online format, enabling real-time communication with investors [3][5]. Group 2: Participation Information - Investors can submit questions from October 9, 2025, to October 15, 2025, by visiting the Roadshow Center's website or via the company's email [6][9]. - The company will address commonly asked questions during the briefing [3][6]. Group 3: Contact Information - Investors can reach out to the company for inquiries regarding the briefing through phone, fax, or email [7][9]. - Contact details include a phone number (0533-3587766) and fax (0533-3587768), with email correspondence directed to shinva@163.com [8][9].

Core Viewpoint - Xinhua Medical (600587.SH) has clarified that its subsidiary did not participate in the research and development of photoresist products, focusing instead on its own innovations in medical technology [1] Group 1: Company Developments - The company has completed the product design and functional prototype development of its lower limb exoskeleton robot [1] - The patent application for the exoskeleton robot was accepted by the National Intellectual Property Administration in January 2025 [1] - Currently, the company is in the stage of optimizing the prototype and conducting preclinical tests [1]

证券代码：600587 证券简称：新华医疗 公告编号：临 2025-040 山东新华医疗器械股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 10 月 9 日（星期四）至 10 月 15 日（星期三）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@16 3.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 10 月 16 日 （星期四） 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财务指标的具体情况与投资者进行 ...

Core Viewpoint - Xinhua Medical's stock price has shown fluctuations, with a recent decline of 2.10% and a total market capitalization of 10.192 billion yuan, indicating potential investor concerns and market dynamics [1]. Financial Performance - For the first half of 2025, Xinhua Medical reported operating revenue of 4.79 billion yuan, a year-on-year decrease of 7.64%, and a net profit attributable to shareholders of 386 million yuan, down 20.35% compared to the previous year [2]. - Cumulative cash dividends since the company's A-share listing amount to 812 million yuan, with 455 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Xinhua Medical reached 39,300, an increase of 0.82% from the previous period, while the average circulating shares per person decreased by 0.81% to 15,386 shares [2]. - The top three circulating shareholders include Huabao Zhongzheng Medical ETF, holding 16.0931 million shares (an increase of 196,600 shares), and Hong Kong Central Clearing Limited, holding 7.9202 million shares (an increase of 413,000 shares) [3]. Business Overview - Xinhua Medical, established on April 18, 1993, and listed on September 27, 2002, operates primarily in the medical device and pharmaceutical equipment sectors, with a revenue composition of 35.16% from medical device manufacturing, 31.23% from medical trade, 24.43% from pharmaceutical equipment, 7.05% from medical services, and 2.12% from other sources [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and equipment, and is involved in various concept sectors including mid-cap, medical waste treatment, in vitro diagnostics, smart healthcare, and private hospitals [1].

Market Overview - On September 17, the medical device sector experienced a decline of 0.22%, with Toujing Life leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Notable gainers in the medical device sector included: - Hualan Biological (301093) with a closing price of 39.01, up 5.20% and a trading volume of 85,900 shares, totaling a transaction value of 330 million yuan [1] - Xinhua Medical (600587) closed at 17.16, up 5.08% with a trading volume of 451,500 shares, totaling 767 million yuan [1] - Haooubo (688656) closed at 168.52, up 5.00% with a trading volume of 16,600 shares, totaling 272 million yuan [1] - Conversely, the following companies saw significant declines: - Toujing Life (300642) closed at 24.55, down 7.53% with a trading volume of 168,900 shares, totaling 426 million yuan [2] - Jimin Health (603222) closed at 13.22, down 4.06% with a trading volume of 748,900 shares, totaling 995 million yuan [2] - Meihua Medical (301363) closed at 27.31, down 2.95% with a trading volume of 153,300 shares, totaling 422 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 894 million yuan from institutional investors, while retail investors contributed a net inflow of 818 million yuan [2] - Notable capital flows included: - Haooubo (688656) with a net inflow of 39.06 million yuan from institutional investors, but a net outflow of 23.69 million yuan from speculative funds [3] - Xinhua Medical (600587) had a net inflow of 38.89 million yuan from institutional investors, with a net outflow of 64.90 million yuan from speculative funds [3] - Hualan Biological (301093) recorded a net inflow of 24.68 million yuan from institutional investors, while retail investors saw a net outflow of 25.99 million yuan [3]

Core Viewpoint - The company, Xinhua Medical, is focusing on the development of exoskeleton robots for medical rehabilitation, with a functional prototype of a lower limb exoskeleton robot completed and a patent application accepted by the National Intellectual Property Administration of China [1] Group 1: Product Development - The lower limb exoskeleton robot is designed with a modular approach, catering to the full cycle of rehabilitation needs from passive training in the acute phase to resistance training in the chronic phase [1] - The product targets various patient groups, including those with post-stroke hemiplegia, spinal cord injuries, and post-orthopedic surgery, making it suitable for hospitals, communities, homes, and elderly care institutions [1] Group 2: Financial Performance - For the reporting period, the company achieved an operating revenue of 4.79 billion yuan, representing a year-on-year decrease of 7.64% [1] - The net profit attributable to the parent company was 386 million yuan, down 20.35% year-on-year [1]

Investment Rating - The report maintains a "Recommended" investment rating for Xinhua Medical (600587) with a target price of 20 yuan [2][7]. Core Views - The company reported a revenue of 4.79 billion yuan for the first half of 2025, a decrease of 7.64% year-on-year, and a net profit attributable to shareholders of 386 million yuan, down 20.35% [2][7]. - The pharmaceutical equipment segment shows steady growth while the company is gradually divesting low-margin businesses [2][7]. - The overall revenue decline is primarily due to reduced income from medical devices and medical trade products [2][7]. - The company is expanding its international market presence, with overseas revenue increasing by 18.69% to 124 million yuan in the first half of 2025 [2][7]. - The gross margin decreased to 25.21%, down 1.44 percentage points, attributed to a lower proportion of high-margin medical device revenue [2][7]. - The company expects net profits for 2025-2027 to be 800 million, 930 million, and 1.03 billion yuan, respectively, with corresponding EPS of 1.32, 1.53, and 1.69 yuan [2][7]. Financial Summary - Total revenue for 2024 is projected at 10.021 billion yuan, with a year-on-year growth rate of 0.1% [2][8]. - The net profit attributable to shareholders is expected to reach 798 million yuan in 2025, reflecting a growth rate of 15.4% [2][8]. - The company’s PE ratio is projected to be 12, 11, and 10 for the years 2025, 2026, and 2027, respectively [2][8].

Core Viewpoint - Xinhua Medical (600587.SH) is actively promoting the intelligent development of medical services through the implementation of various logistics robots and an intelligent logistics management system [1] Group 1: Company Overview - Xinhua Medical possesses a range of logistics robots, including full-hospital logistics robots, high-value consumable logistics robots, cleaning logistics robots, sterilization logistics robots, low-temperature logistics robots, and stacking robots [1] - The company plays a significant role in hospital material distribution scenarios by leveraging its intelligent logistics management system [1]